Loading
Life sciences · Journal article
Journal of Functional Biomaterials · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Adjuvant therapy following breast cancer surgery remains challenged by systemic toxicity, poor tumor accuracy, and tumor recurrence. Electrospun nanofibers have emerged to address these concerns. Their high surface area, tunable porosity, and controlled drug release properties enable sustained, site-specific drug release directly to the tumor site while sparing healthy tissues and reducing systemic exposure. The scientific question of the current review is centered on whether the utilization of electrospun nanofibers prevents tumor recurrence after breast cancer surgery. Electrospun nanofiber design determinants, including composition, architecture, creation techniques, and drug-loading strategies, are outlined in the following analysis. Subsequently, it also examines different therapeutic approaches, such as protein- and peptide-loaded fibers, stimuli-responsive nanofibers, natural anticancer compounds, immunomodulators, and combination therapies. Notably, the application of electrospun nanofibers in breast cancer treatment, overcoming tumor microenvironment barriers, and preventing post-surgical recurrence is reported. Finally, limitations associated with clinical translation, such as large-scale production, regulatory approval, sterilization, and long-term efficacy, are also addressed. Collectively, the evidence indicates that electrospun nanofibers show great potential for localized cancer therapy by enabling controlled drug release and reducing systemic exposure, though clinical validation remains the critical unmet step.